Cargando…
Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754364/ https://www.ncbi.nlm.nih.gov/pubmed/26925113 http://dx.doi.org/10.5114/aoms.2016.57577 |
_version_ | 1782416001516699648 |
---|---|
author | Gut, Paweł Czarnywojtek, Agata Fischbach, Jakub Bączyk, Maciej Ziemnicka, Katarzyna Wrotkowska, Elżbieta Gryczyńska, Maria Ruchała, Marek |
author_facet | Gut, Paweł Czarnywojtek, Agata Fischbach, Jakub Bączyk, Maciej Ziemnicka, Katarzyna Wrotkowska, Elżbieta Gryczyńska, Maria Ruchała, Marek |
author_sort | Gut, Paweł |
collection | PubMed |
description | Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the classical endocrine glands and the diffuse neuroendocrine system. These cells are a potential source of transformation into neuroendocrine tumors. The awareness of potential causes influencing the false results of its concentrations simplifies diagnosis and treatment. One of the disadvantages of this marker is its non-specificity and the existence of a number of pathological processes leading to an increase in its concentration, which often results in confusion and diagnostic difficulties. The molecular structure is characterized by a number of sites susceptible to the proteolytic activity of enzymes, resulting in the formation of a number of biologically active peptides. Presumably they act as precursors of active proteins. Chromogranin expression correlates with the amount of secretory vesicles in neuroendocrine cells. The peptide chain during biochemical changes becomes a precursor of biologically active proteins with a wide range of activities. There are a number of commercially available kits for the determination of chromogranin A, which differ in methodology. We present the evaluation of chromogranin A as a marker of neuroendocrine tumors in clinical practice and the possible factors that may affect the outcome of its concentration. |
format | Online Article Text |
id | pubmed-4754364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-47543642016-02-26 Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls Gut, Paweł Czarnywojtek, Agata Fischbach, Jakub Bączyk, Maciej Ziemnicka, Katarzyna Wrotkowska, Elżbieta Gryczyńska, Maria Ruchała, Marek Arch Med Sci State of the Art Paper Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both the classical endocrine glands and the diffuse neuroendocrine system. These cells are a potential source of transformation into neuroendocrine tumors. The awareness of potential causes influencing the false results of its concentrations simplifies diagnosis and treatment. One of the disadvantages of this marker is its non-specificity and the existence of a number of pathological processes leading to an increase in its concentration, which often results in confusion and diagnostic difficulties. The molecular structure is characterized by a number of sites susceptible to the proteolytic activity of enzymes, resulting in the formation of a number of biologically active peptides. Presumably they act as precursors of active proteins. Chromogranin expression correlates with the amount of secretory vesicles in neuroendocrine cells. The peptide chain during biochemical changes becomes a precursor of biologically active proteins with a wide range of activities. There are a number of commercially available kits for the determination of chromogranin A, which differ in methodology. We present the evaluation of chromogranin A as a marker of neuroendocrine tumors in clinical practice and the possible factors that may affect the outcome of its concentration. Termedia Publishing House 2016-02-02 2016-02-01 /pmc/articles/PMC4754364/ /pubmed/26925113 http://dx.doi.org/10.5114/aoms.2016.57577 Text en Copyright © 2016 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | State of the Art Paper Gut, Paweł Czarnywojtek, Agata Fischbach, Jakub Bączyk, Maciej Ziemnicka, Katarzyna Wrotkowska, Elżbieta Gryczyńska, Maria Ruchała, Marek Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls |
title | Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls |
title_full | Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls |
title_fullStr | Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls |
title_full_unstemmed | Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls |
title_short | Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls |
title_sort | chromogranin a – unspecific neuroendocrine marker. clinical utility and potential diagnostic pitfalls |
topic | State of the Art Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754364/ https://www.ncbi.nlm.nih.gov/pubmed/26925113 http://dx.doi.org/10.5114/aoms.2016.57577 |
work_keys_str_mv | AT gutpaweł chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls AT czarnywojtekagata chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls AT fischbachjakub chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls AT baczykmaciej chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls AT ziemnickakatarzyna chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls AT wrotkowskaelzbieta chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls AT gryczynskamaria chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls AT ruchałamarek chromograninaunspecificneuroendocrinemarkerclinicalutilityandpotentialdiagnosticpitfalls |